Lung Cancer Clinical Trials

In most cases, yes. The majority of lung cancer trials require molecular profiling results to determine eligibility. Comprehensive next-generation sequencing (NGS) and PD-L1 testing are standard. If your tumor has not been tested, ask your oncologist about ordering these tests, as they are covered by most insurance plans.

Yes. While small cell lung cancer has fewer approved therapies, there are active trials testing antibody-drug conjugates, novel immunotherapy combinations, and targeted agents like DLL3-directed therapies. These trials are particularly important because treatment options for small cell lung cancer remain more limited than for non-small cell.

Many trials now include patients with brain metastases, particularly if the metastases are stable or have been treated. Some trials specifically evaluate drugs that cross the blood-brain barrier. Check the eligibility criteria carefully, as policies on brain metastases vary significantly between studies.

When a targeted therapy fails, a repeat biopsy or liquid biopsy can identify the resistance mechanism. Clinical trials testing next-generation drugs designed to overcome specific resistance mutations are available for many scenarios. Your oncologist can help identify trials matched to your resistance profile.

Most lung cancer trials provide at minimum the current standard of care. New treatments are typically tested in addition to or compared against standard therapy, not instead of it. Placebo-only arms are essentially never used in advanced lung cancer trials.